תבנית:תרופה/סביבו - Sebivo
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) |
J05AF |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | *Telbivudine 600MG âJ05AF11
|
| צ×רת ××ª× | PER OS |
| צ×רת ××× ×× | FILM COATED TABLETS |
| ×ת×××× | Treatment of chronic hepatitis B in patients with evidence of viral replication and active liver inflammation in adults over 16 years of age.The following points should be considered when initiating therapy with Sebivo:- For HBeAg - positive patients, Sebivo treatment should only be initiated in patients with baseline HBV DNA < 9log 10 copies/ml and baseline ALT>or= 2x ULN.- For HBeAg - negative patients, Sebivo treatment should only be initiated in patients with baseline HBV DNA < 7log 10 copies/ml.
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/ס×××× - Sebivo | |
| ×ת××ת ××× ×× | Posology and method of administration |
| ×ת××××ת × ×× | Contraindications |
| ת×פע×ת ××××× | Undesirable effects |
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× | |
| ×¢××× ×צר×× | *×¢××× ×צר×× |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ס×××× Â® ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | NOVARTIS PHARMA STEIN AG, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | NOVARTIS ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 09/2006. ר×ש××× ×ת×ר××: 12/2012 |
| ת×ר×× ×¢×××× ××ר×× | 15/05/19 |
ת××× ×ª ×ר×××
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: ס×××× - Sebivo
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/ס×××× - Sebivo}}
×:
{{תר×פ×/ס×××× - Sebivo
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־14 במאי 2019 ב־21:55